 BRISBANE, Calif., Sept. 08, 2022 GLOBE NEWSWIRE -- GT Biopharma, Inc. NASDAQ: GTBP, a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Companys proprietary natural killer NK cell engager, TriKE platform, today announced that management will present in-person at H.C. Wainwrights 24th Annual Global Investment Conference taking place September 12-14, 2022 at the Lotte New York Palace. Company management will also be participating in 1x1 meetings during the event. 